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ABSTRACT
Cyclin D1 is an important cell cycle regulator but in cancer its overexpression also
increases cellular migration mediated by p27KlP1 stabilization and RhoA inhibition.
Recently, a common polymorphism at the exon 4-intron 4 boundary of the human cyclin
D1 gene within a splice donor region was associated with an altered risk of developing
cancer. Altered RNA splicing caused by this polymorphism gives rise to a variant cyclin
D1 isoform termed cyclin D1b, which has the same N-terminus as the canonical cyclin
D1a isoform but a distinct C-terminus. In this study we show that these different
isoforms have unique properties with regard to the cellular migration function of cyclin
D1. Whereas they displayed little difference in transcriptional co-repression assays on
idealized reporter genes, microarray cDNA expression analysis revealed differential
regulation of genes including those that influence cellular migration. Additionally, while
cyclin D1a stabilized p27

KIP1

and inhibited RhoA-induced ROCK kinase activity,
KIP1

promoting cellular migration, cyclin D1b failed to stabilize p27
or inhibit ROCK kinase
activity and had no effect on migration. Our findings argue that alternate splicing is an
important determinant of the function of cyclin D1 in cellular migration.

The cyclin D1 gene was initially cloned as a breakpoint rearrangement in
parathyroid adenoma (1). Subsequent studies confirmed increased cyclin D1
abundance in a variety of tumors including breast and gastrointestinal tumors (2).
Molecular analysis demonstrated the cyclin D1 gene encodes the regulatory subunit of
a holoenzyme that phosphorylates and inactivates the retinoblastoma protein, pRb.
Immunoneutralizing and antisense experiments revealed the requirement for cyclin D1
in progression through the early G1 phase of the cell cycle (reviewed in (2)). In addition
to binding Cdks, cyclin D1 associates with several different intracellular proteins
including the estrogen receptor (ERα), PPARγ, P/CAF (p300/CBP associated factor)
(3,4) and the cyclin D1 myb-like binding protein (DMP1) (5-8). Cyclin D1 binds to ERα in
breast cancer cells and overcomes the BRCA1-mediated repression of ERα activity
(9,10). Homozygous deletion of the cyclin D1 gene results in mice with failure of
terminal alveolar breast development during pregnancy, increased basal and UVinduced apoptosis, retinal apoptosis, defective angiogenesis, hepatic steatosis, and
defective cellular migration (4,11-14).
Previous epidemiological and clinical observations have demonstrated a
correlation between cyclin D1 overexpression and cellular metastases (15). Molecular
genetic analysis subsequently revealed a key role for cyclin D1 in cellular adhesion and
migration (14). In particular, cyclin D1-deficient cells showed enhanced cellular
adhesion and reduced migration into a wound, and genetic complementation
experiments established a requirement for the CDK-binding but not the pRB-binding
domain of cyclin D1 to rescue the cell migratory defect (16,17). Together, these studies
demonstrated a key role for cyclin D1 in cell migration, including bone marrow-derived
macrophages, fibroblasts, and mammary epithelial cells (14,16,17).
Recently, a common polymorphism identified in the human cyclin D1 gene was
found to be associated with an increased risk of cancer development (18-22). This
polymorphism (A870G), located at the splice donor region at the exon 4-intron 4
boundary, modulates the efficiency of alternate splicing between exon 4 and
5. As a result of the altered splicing which occurs, the coding region downstream is
altered such that the amino acid sequence of the carboxyl-terminus of cyclin D1 is
altered (18). Thus, the two isoforms of cyclin D1 produced, the canonical isoform
termed cyclin D1a and the alternately spliced isoform termed cyclin D1b, are identical in
their N-termini but distinct in their C-termini. Notably, clinical studies have associated
this polymorphism with an increased risk of colon and rectal cancer, early-onset
squamous cell carcinoma, head and neck cancer, and transitional cell carcinoma of the
bladder (23). Elegant in vitro analyses have demonstrated that the cyclin D1a and D1b
isoforms have similar half lives in cultured cells, however, the cyclin D1b isoform is
primarily nuclear in subcellular localization and relatively more resistant to
phosphorylation-dependent nuclear export (24). Cyclin D1a blocks cells at the G1 phase
whereas cyclin D1b blocks cells at the G0 phase in some (23), but not all studies (25).
Notably, while both isoforms encode regulatory subunits, cyclin D1b has a reduced
capacity to phosphorylate pRb (25,26). Yet despite serving as a less effective

component of this pRb kinase, cyclin D1b conveys a greater transforming capacity
which enhances colony formation of NIH3T3 cells. Thus, the basis for the enhanced
transforming ability of cyclin D1b has been unclear.
KIP1

The Cdk inhibitor p27

inhibits most cyclin/Cdk complexes, including cyclin

E/Cdk2 and cyclin D/Cdk4 (27). In the majority of studies, reduced p27
KIP1

KIP1

in tumors

correlates with a poorer prognosis (28-31). p27
plays an important role in regulating
cellular migration through regulating either Rac (32), Rho GTPase activity (16,33) or
Stathmin function (34). Mechanistic analyses presented here reveal that cyclin D1b
KIP1

evades binding to p27
which may explain the increased cell transforming activity of
this isoform. Furthermore, cyclin D1b lacks the pro-migratory function of cyclin D1a,
implicating the C-terminal region and alternate splicing as important determinants of this
function.
Experimental procedures
+/+

-/-

Cell culture - Cyclin D1 and cyclin D1 primary mouse embryonic fibroblasts (MEFs)
cultures were prepared as described previously (4) and passaged by the original 3T3
protocol (35). Human kidney 293T and MCF-7 cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing penicillin and streptomycin (100 mg of
each/liter) and supplemented with 10% FBS.
-/-

Retroviral production and infection - Retroviral production and infection of cyclin D1
3T3 cells were previously described (16). Fluorescence-activated cell sorting (FACS)
(DakoCytomation MoFlo; Dako Denmark) sorted GFP+ cells were used for subsequent
analysis.
118

Immunofluorescence - Phalloidin, paxillin and tyrosine phosphorylated paxillin (pY )
staining were conducted as previously described (14,16). The samples were visualized
on a Zeiss LSM 510 META Confocal Microscope with a 63× objective.
-/-

Immunoprecipitations and Western blotting - Cyclin D1 MEFs or 3T3 cells infected
with GFP vector control or cyclin D1 wild type (D1a) or splice variant (D1b) were lysed
in immunoprecipitation (IP) buffer (10 mM Tris-HCL at pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% IGEPAL CA630, 10% glycerol, 1 mM
sodium orthovanadate and protease inhibitor cocktail (Boehringer Mannheim). For each
IP, 1 ml lysate (1 mg protein) and 10 µl anti-FLAG M2-agarose affinity gel (Sigma, St.
o

Louis, MO) were incubated overnight at 4 C. Immunoprecipitates were washed 5 times
in IP buffer, and 20 µl of 2×sample buffer was added to the bead pellet. The
immunoprecipitates, as well as 50 µg of proteins from the corresponding lysates were
subjected to Western blotting as previously described (36). The following antibodies
were used for Western blotting: mouse M2 anti-FLAG antibody, antivinculin antibody
(Sigma, St. Louis, MO), and anti β-tubulin antibody, mouse anti-cyclin D1 antibody

KIP1

(DCS-6), rabbit polyclonal anti-p27
antibody (C-19), rabbit polyclonal antibody for
Ser3 phospho-ADF/cofilin (Santa Cruz Biotechnology, Santa Cruz, CA).
Time-lapse video - For time-lapse observation of cell movement, cells were plated in
12 well plates in DMEM with 10% FCS and HEPES. Cells were placed in a
o

temperature- and CO2-controlled incubator to maintain the temperature at 37 C and
CO2 at 5%. The cell movement videos were snapped at 5 minute intervals for 2 hours
by using a Zeiss Axiovert 200M Inverted Microscope System. The cell movement
velocity was determined by tracing several single cells at different time points using
MetaMorph software.
Mammalian two-hybrid and luciferase reporter gene assays - Mammalian twohybrid was performed by following the manufacturer’s instruction (Promega) and was
KIP1

described previously (17). Human p27 , cyclin D1a or D1b cDNAs were cloned into
pBIND vector and pACT vector to generate fusion proteins with the DNA binding
domain of GAL4 (Gal4-p27
(VP16-p27

KIP1

Kip1

, Gal4-D1a, Gal4-D1b) and the activation domain of VP16

, VP16-D1a, VP16-D1b), respectively. Gal4-PPARγ, Gal4-AR, and Gal4KIP1

NRF1 were previously described (3,4,37). Gal4p27 , VP16-cyclin D1, and pG5luc,
which contains five Gal4 binding sites upstream of a minimal TATA box and the firefly
KIP1

luciferase gene (Promega) or Gal4-cyclin D1, VP16-p27
and pG5luc were
cotransfected into MCF-7 cells with Superfect transfection reagent. Two days after
transfection, the cells were lysed and luciferase activity quantitated as previously
described (4). Luciferase activity was normalized for transfection efficiency using a βgalactosidase reporter (CMVβ-gal) as an internal control.
Northern blot and pulse chase analysis - Total RNA samples were prepared from
-/-

cyclin D1 3T3 cells infected with cyclin D1a, D1b, or vector control with the Trizol
reagent (Invitrogen). For Northern blot, 10 µg of RNA per sample was separated on
0.9% formaldehyde-agarose gel, transferred, and hybridized by using Rapid-hyb Buffer
KIP1

(Amersham/GE Healthcare, Piscataway, NJ). Mouse p27
32

probe, mouse β-actin

probe, and human cyclin D1 probe were labeled with [α P]dCTP by using the Readyto-go kit (Amersham/GE Healthcare, Piscataway, NJ). Mouse p27

KIP1

and mouse β-

-/-

actin probes were RTPCR products. 1 µg of total RNA from cyclin D1 MEFs infected
with cyclin D1a was used for cDNA synthesis with the Superscript Reverse
Transcriptase (Invitrogen). RT-PCR products were obtained with the following primers:
Kip1

p27
primers: forward: 5’CGTGAGAGTGTCTAACGGG-3’ and reverse: 5’CGAGTCAGGCATTTGGTCC-3’. β-actin primers: forward: 5’TGTTACCAACTGGGACGACA-3’ and reverse: 5’-AAGGAAGGCTGGAAAAGAGC-3’.
The human cyclin D1 probe was the fragment between HindIII and NcoI from MSCVo

cyclin D1a-IRESGFP retroviral vector. The filters were exposed to X-ray films at –80 C.
Pulse chase analysis was conducted as previously described (38).

-/-

Real-time RT-PCR - Total RNA samples from cyclin D1 cells transfected with MSCVIRESGFP, MSCV-cyclin D1a-IRES-GFP or MSCVcyclin D1b-IRES-GFP were subjected
to DNase I (RQ1 DNase: Promega Corp, Madison, WI) treatment to remove
contaminating DNA from RNA preparations followed by their re-purification using
Qiagen RNAEasy RNA columns (Qiagen, Valencia, CA). Equal amounts of purified
RNA samples were reverse transcribed using Iscript Reverse transcriptase kit (Bio-Rad,
Hercules, CA) to form cDNA which was then subjected to SYBR Green based RealKIP1

Time PCR relative quantification method for amplification of p27
transcripts using
standard hot-start reaction mixes and conditions (39) in an ABI Prism 7900HT (Applied
KIP1

Biosystems, Foster City, CA). The primers used for amplification of p27
were:
forward 5’ TCTCTTCGGCCCGGTCAAT 3’ and reverse 5’
GGGGCTTATGATTCTGAAAGTCG 3’. Amplification of 18S rRNA housekeeping gene
transcript (primer ref (40)) was performed in every sample and the obtained Ct values
KIP1

for each sample were used for normalization of data for p27
KIP1

SDS 2.3 software. To calculate the fold change in p27

expression in ABI Prism

gene expression between

various treatments Ct values obtained from amplification of p27
IRES-GFP were used for calibration.

KIP1

transcripts in MSCV-

Microarray analysis - Total RNA (5µg) was reverse transcribed using Superscript III
First-Strand Synthesis System (Invitrogen) using a HPLC purified T7-dT24 primer
(Sigma Genosys) which contains the T7 polymerase promoter sequence. The single
stranded cDNA was converted to double stranded cDNA using DNA polymerase I
(Promega) and purified by cDNA spin column purification using GeneChip Sample
Cleanup Module (Affymetrix). The double stranded cDNA was used as a template to
generate biotinylated cRNA using Bioarray HighYield RNA Transcription Labeling Kit
(Enzo) and the labeled cRNA purified by GeneChip Sample Cleanup Module
(Affymetrix). 15µg of cRNA was fractionated to produce fragments between 35–200 bp
using 5x Fragmentation buffer provided in the Cleanup Module. The sample was
hybridized to mouse 430 2.0 microarray (Affymetrix) representing approximately 39,000
well-characterized mouse transcripts. The hybridization and washing steps were carried
out in accordance with Affymetrix protocols for eukaryotic arrays. The arrays were
scanned at 570nm with a confocal scanner from Affymetrix.
Array data analysis - Analysis of the arrays was performed using R-statistics package
and the limma library of the Bioconductor software package (37). Arrays were
normalized using robust multiarray analysis (RMA), and P-value of
0.05 was applied as criteria for statistically significant differentially expressed genes
between Cyclin D1a or Cyclin D1b rescued 3T3 compared to GFP control. GO tree
analysis of gene function analyzed by “Webgestalt”
(http://bioinfo.vanderbilt.edu/webgestalt) (41) and affymetrix gene annotation.

Results
Genes associated with cell migration are preferentially regulated by cyclin
D1a but not cyclin D1b. Cyclin D1a functions as a transcriptional coregulator in part by
recruiting HDAC and controlling p300 HAT activity (2,42,43). For example, cyclin D1a
inhibits PPARγ signaling and transactivation in vitro and in vivo (4,42). To compare the
transcriptional repression function of cyclin D1b, we evaluated its effects on PPARγ
activity using a heterologous reporter system in which PPARγ was linked to the Gal4DNA binding domain. Consistent with prior studies, cyclin D1a inhibited PPARγ activity
while cyclin D1b also repressed PPARγ activity to a similar extent (Fig. 1A). Cyclin D1
also inhibits mitochondrial biogenesis, in part by inhibiting the transcriptional activity of
NRF1 (37). Herein, both cyclin D1a and cyclin D1b inhibited NRF1 activity (Fig. 1A).
Consistent with recent studies (44), cyclin D1b repressed androgen receptor activity. To
further compare the effects of the cyclin D1 isoforms on transcription, we performed a
-/-

genome-wide analysis of how they affected gene expression in cyclin D1 mouse
-/-

embryo fibroblast derived 3T3 cells. The cyclin D1 cells were transduced with specific
retroviral vectors. Previous work has shown that cyclin D1 regulates the expression of
genes involved in cellular migration in early passage MEFs (16). 3T3 cells transduced
with retroviral vectors expressing each cyclin D1 isoform were processed for mRNA
analysis. Similar levels of cyclin D1 isoform were expressed by each vector as
determined by Western blotting (Fig. 2C, Fig. 3A). We found that 19 genes were
regulated concordantly by both cyclin D1a and cyclin D1b (Fig. 1B). Distinct genes were
regulated by cyclin D1a vs. cyclin D1b. Cyclin D1a expression altered the abundance of
661 genes, of which 397 genes were induced and 264 genes repressed >1.3-fold,
compared with vector control. Cyclin D1b regulated expression of 60 genes, 1/3 of
which (19 genes) were regulated concordantly by cyclin D1a. Cyclin D1a regulated a
distinct cluster of genes that function to promote cellular migration and invasion. These
genes were not regulated by cyclin D1b (Supplemental Data 1, Table 1, For full details
the GEO accession number obtained is GSE9161
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi
?token=zfellwagiuaagfa&acc=GSE9161). Cyclin D1b regulated genes function in DNAdependent transcription and nucleosome assembly (Supplemental Data 2, Table 2).
Cellular migration is promoted by cyclin D1a but not cyclin D1b. MEFs
genetically deficient in cyclin D1 spread with a circumferential distribution of adherent
focal contacts (16). Cyclin D1 promotes cellular migration of bone marrow
macrophages, fibroblasts, mammary epithelial cells and vascular endothelial cells
(14,16,45). To evaluate whether both cyclin D1 isoforms promote focal contact
distribution and cellular migration, retroviral transduced cells co-expressing green
fluorescence protein (GFP) via an internal ribosomal entry site (IRES) were sorted after
-/-

transduction for analysis. Consistent with previous studies, cyclin D1 MEFs assumed
a flattened spread morphology by phase contrast microscopy (Supplemental Data 3).
Cell contacts were monitored by confocal microscropy using antibodies specific for
tyrosine-phosphorylated paxillin (Y118). Consistent with previous observations, cyclin
-/-

D1 MEFs showed a peripheral distribution of focal contacts as revealed by tyrosine-

phosphorylated paxillin (Y118) (Fig. 2A). Cyclin D1a-expressing cells markedly reduced
the peripheral distribution of tyrosine phosphorylated paxillin. In contrast, cyclin D1b
failed to reverse this phenotype (Fig. 2A).
To compare effects on cell migration, GFP positive cells were examined by
phase contrast video microscopy. Previous studies have demonstrated that cyclin D1
regulates F-actin organization and promotes migration through inhibition of the RhoA-/-

regulated ROCK kinase (16,17). Consistent with these studies, cyclin D1 MEFs
expressing cyclin D1a appeared polarized (Fig. 2A) and phalloidin staining
demonstrated a reduction in F-actin staining. In contrast, although similar protein levels
were expressed in cyclin D1b-transduced cells, no alteration in cellular morphology was
observed (Fig 2A). Cellular movement velocity was determined at regular 5 min
intervals. As expected, velocity was enhanced by expression of cyclin D1a but not by
the cyclin D1b isoform (Fig. 2B).
Cyclin D1 enhances cellular migration by inhibiting ROCK kinase activity as
evidenced by reduced phosphorylation of the actin-depolymerizing protein cofilin at
-/-

serine 3 (Ser3) (17). In transduced cyclin D1 cells, cyclin D1a reduced ROCK activity
as evidenced by a ~2-fold reduction in Ser3 phosphorylation of cofilin relative to vectorKIP1

only transduced control cells (Fig. 2C). Additionally, cyclin D1a induced p27
abundance ~5-fold (Fig. 2C). In contrast, cyclin D1b did not significantly affect either
Ser3cofilin phosphorylation or p27
KIP1

p27

KIP1

abundance (Fig. 2C).

is stabilized by cyclin D1a but not cyclin D1b. Because of the strength of

the evidence that p27

KIP1

control is critical for cyclin D1a-mediated cellular migration
KIP1

(17), we further compared how cyclin D1b affected p27
to gain further insight into the
basis for its differential effects on cellular migration. Replicate experiments with different
-/-

KIP1

cyclin D1 MEF preparations indicated that p27
levels were induced ~3-fold on
average by cyclin D1a (Fig. 3A). In contrast, cyclin D1b transduction reduced p27KlP1
abundance ~40%. This difference was unrelated to levels of isoform expression as
similar levels of cyclin D1a and cyclin D1b were produced in cells as confirmed by
KIP1

Western blotting (Fig. 3A). p27
is regulated at multiple levels including transcription
(46), translation (47) and post-translational (48). Because cyclin D1a acts as a
transcriptional co-regulator we examined whether cyclin D1 regulated p27

KIP1

mRNA

KIP1

abundance. However, neither isoform affected the steady-state levels of p27
mRNA
as determined by Northern blot analysis or QT-PCR (Fig. 3B,C). We next examined
KIP1

whether the increased levels of p27
-/-

protein reflected an increase in protein stability.

Cyclin D1 MEFs were transduced with retroviral vectors encoding cyclin D1a or cyclin
D1b and protein abundance determined after cycloheximide treatment. A representative
example (Fig. 4A) and mean data of multiplicate experiments (Fig. 4B) are shown. In
cells transduced by cyclin D1a, the relative abundance of p27

KIP1

protein was increased

~2.5 fold at each time point determined after protein synthesis inhibition by
cycloheximide, compared to cyclin D1b (Fig. 4). Pulse chase analysis was conducted to
KIP1

determine the effect of the cyclin D1 isoforms on newly synthesized p27
-/-

(Fig. 4C).

Cyclin D1 3T3s were transduced with retroviral vectors encoding cyclin D1a or cyclin
KIP1

D1b. The rate of newly synthesized p27
was increased approximately 2-fold by
cyclin D1a 1 hr after the initiation of the pulse chase, but was similar by 2 hrs. Together
KIP1

these results argue that cyclin D1a increases p27
levels through promoting
stabilization of the protein when compared with the effects of cyclin D1b.
Cyclin D1b displays reduced binding to p27

KIP1

KIP1

. Previous studies have

documented a physical interaction between p27
and cyclin D1a by
immunoprecipitation and mammalian two-hybrid assays (17,49). We therefore
compared the ability of cyclin D1b to interact with p27

KIP1

in these assays. In a

KIP1

mammalian two hybrid system, we confirmed that cyclin D1a interacted with p27
and
that point mutation of the cdk4-binding domain of cyclin D1a (D1KE) abrogated this
interaction (Fig. 5B). By comparison, the cyclin D1b isoform exhibited a relative ~80%
KIP1

reduction in p27
interaction. As the cyclin D1a and cyclin D1b are similar for the
amino acids encoded by exons 1-4 but differ in their carboxyl terminal amino acid
structure (Fig. 5A), these studies implicated the cyclin D1a carboxyl terminus encoded
Kip1

by exon 5 in the interaction with p27 . A carboxyl terminal deletion mutant of cyclin
D1a residues encoding exon 5 (Cyclin D1N2) was therefore generated. This mutant of
KIP1

cyclin D1a was defective in p27

interaction in mammalian 2-hybrid (Fig. 5B). Similar
KIP1

results were obtained by a reciprocal analysis in which the p27
and cyclin D1
polypeptides were swapped in as fusions to the Gal4 DNA-binding domain and VP16
transactivation domain employed in this system (Fig. 5B, right hand panel). We
confirmed these findings by an immunoprecipitation analysis conducted in retroviral
-/-

vector-transduced cyclin D1 MEFs that were subjected to GFP-based cell sorting (Fig.
5C). As before, similar levels of cyclin D1a and cyclin D1b were expressed as
documented by Western blotting (Fig. 5C; Input). Immunoprecipitation using the aminoterminal FLAG epitope included in the construct confirmed similar amounts of cyclin D1
protein. Western analysis of the cyclin D1 immunoprecipitates identified p27

KIP1

KIP1

associated with cyclin D1a. However, only ~1/10 of the amount of p27
present in
these immunoprecipitates was present in a similar cyclin D1b immunprecipitate in
replicate experiments (Fig. 5C). The role of the cyclin D1a carboxyl terminus in
interaction with Cdk4 in mammalian 2-hybrid was next assessed. The cyclin D1b and
cyclin D1N2 displayed an approximately 50% reduction in interaction compared with
cyclin D1a (Fig. 5D).
Discussion
The present study extends the understanding of cyclin D1 splice variants (26) by

demonstrating that the two distinct isoforms differ in their fundamental biological and
biochemical properties. An unbiased genomic approach was used to identify genes
regulated by cyclin D1a vs. cyclin D1b. This type of study does not necessarily identify
direct transcriptional targets but demonstrated approximately 1/3 or the genes regulated
in response to cyclin D1b were also regulated by cyclin D1a. The functions of genes
regulated by cyclin D1b only include genes involved in DNA-dependent transcription
and nucleosome assembly. Previous studies had characterized transcriptional
repression function of cyclin D1a implicating a predicted helix-loophelix domain (4).
This domain is conserved with cyclin D1b, and both cyclin D1a and cyclin D1b
maintained repression function of the heterologous transcription factor domains for the
AR, NRF1 and PPARγ.
Cyclin D1a induces cellular polarity and migration, increasing cellular movement
velocity. The molecular mechanism for these effects involves an inhibition of Rho
signaling, as evidenced by a specific reduction in the phosphorylation of the actin
severing protein cofilin at Ser3. In contrast, cyclin D1b failed to promote cellular
polarization and cellular migration, failed to inhibit cofilin phosphorylation, and failed to
KIP1

stabilize p27

. Associated with these defects, cyclin D1b was also defective in its
KIP1

ability to effectively interact with p27 , as measured in mammalian two-hybrid assays
and co-immunoprecipitations from mouse cells.
KIP1

Cyclin D1a increased the abundance of p27
by promoting the stability of this
important cell regulator. The crystal structure of the amino-terminal 69 residues of the
KIP1

p27

inhibitory domain bound to phosphorylated cyclin A/Cdk2 contributed to the
KIP1

understanding that p27

contains separate binding sites for the cyclin and the kinase
KIP1

(50). One key mechanism governing p27
KIP1

stability involves an SCF ubiquitin ligase

(E3) complex which induces p27
ubiquitination and degradation by the ubiquitinproteosome system. An additional ubiquitin ligase, KPC (KIP1 ubiquitination-promoting
complex) has been described. The mechanisms by which cyclin D1a induce p27
involves regulation of Skp2 expression, protection of p27
association with the cyclin, and the induction of p27

KIP1

KIP1

KIP1

from degradation due to its

phosphorylation at Ser10 (17).

Cyclin D1a regulated expression of genes in 3T3 cells that are known to either
inhibit adhesion and/or promote migration. These findings in 3T3 cells are consistent
with prior findings that cyclin D1a promotes migration in non-transformed cells including
macrophages and mammary epithelial cells (14,16,17). The genes regulated by cyclin
D1a include thrombospondin 1 (TSP-1), procollagen, type VIII, alpha 1 (Col8a1),
junction plakoglobin (Jup), ras homolog gene family, member B (RhoB), and cadherin 2
(Cdh2). Inhibition of TSP-1 from MEFs reverts abnormal migration (16,51). Cadherin 2
(Cdh2) also known as N-cadherin (NCAD) inhibits Schwann cell migration (52). Cyclin
D1a repressed RhoB. Emerging evidence points to a tumor-suppressive role for RhoB
(53-55) which antagonizes Ras/PI3K/Akt-dependent transformation, apoptosis and
metastasis in vivo (56). Stathmin, which was induced by cyclin D1a, promotes cell

motility (34,57). Cde-12/Elmo1 is required for phagocytosis and cell migration (58).
Thus, cyclin D1 downregulates the expression of TSP-1, Cdh2 and RhoB, which inhibit
cell migration while upregulating the expression of Stathmin 1 and Elmo1, which are
required for cell migration.
The human cyclin D1 gene harbors a common polymorphism that has been
associated with increased risk of cancer development. Compared with individuals of the
A/G or G/G genotypes, those harboring the A/A genotype have an increased proclivity
towards tumorigenesis and worse prognosis (18-20,22). The A allele is associated with
synthesis of the cyclin D1b isoform (18). In cells, cyclin D1b has an increased
transforming capacity (26). Our finding that p27
KIP1

KIP1

levels are reduced in cyclin D1b-

expressing cells and that p27
binds cyclin D1b relatively poorly offers one
explanation for why production of this isoform might be associated with increased

KIP1

cancer risk, based on the improved ability of cyclin D1b to evade restraint by p27
compared to cyclin D1a.

as

The current studies demonstrated the importance of the cyclin D1a carboxyl
KIP1

terminus encoded by exon 5 in binding p27 . Cyclin D1b or a carboxyl terminal
deletion mutant of cyclin D1 (cyclin D1N2) either reduced or abolished interaction with
KIP1

p27

KIP1

in mammalian 2-hybrid analysis (Fig. 5A-C). Consistent with our studies of
CIP1

p27
, previous studies of p21
assessed in
S. Cerevisiae using a LexA-op-lacZ system, had shown that deletion of the C-terminal
CIP1

residues (267-295) reduced association with p21
(59). In addition, these prior
studies demonstrated deletion of the cyclin D1a N-terminal 40 residues reduced
CIP1

interaction with p21
indicating the importance of both N and C-terminal interaction
made between the cyclin D1 and the cdk inhibitor proteins.
KIP1

The role of p27
in cellular migration appears to vary with cell and tumor
type. Therefore, the effect of cyclin D1a vs. cyclin D1b on migration may also vary by
cell type. Reintroducing p27

KIP1

into p27

Rho signaling (33). However, p27
KIP1

p27

KIP1

KIP1-/-

cells promotes migration by inhibition of

inhibits cell migration in fibrosarcoma cells, where

binds to and inhibits the function of the microtubule destablizing protein stathmin
KIP1

(34). Binding of p27

to cyclins is important for inhibiting cyclin D/Cdk4 and cyclin
KIP1

E/Cdk2 kinase activity and p27
KIP1

has an important role as a tumor suppressor.

Reduction in p27
levels correlates with tumor aggressiveness. For example, p27
deficiency accelerates cancer formation caused by mutation of the Apc or

KIP1

KIP1

Neu/ErbB2/HER2 genes (39). Moreover, mice lacking even a single copy of p27
have an increased susceptibility to carcinogenesis (60-62), illustrating the importance of
KIP1

its abundance in tumor suppression. Thus, reduction in p27
binding by cyclin D1b
may impact tumor suppressor activity, perhaps in a cell type-specific manner.

We found that cyclin D1a but not cyclin D1b restored defective cellular
-/-

KIP1

migration of cyclin D1 MEFs. Previous studies have demonstrated a role for p27
in promoting cellular migration through binding to RhoA which regulates cytoskeletal
structure, cell adhesion, and cellular migration (33). Cyclin D1a induction of migration
is dependent on p27

KIP1

(17). Our finding of a reduced p27

KIP1

binding capacity for

cyclin D1b suggests that its poor pro-migratory activity reflects a defect in p27
KIP1

KIP1

-

dependent migration. Thus, by evading restraint by p27 , cyclin D1b may favor cell
cycle deregulation at the cost of reduced migratory capability. Further in vivo studies
may be useful to distinguish how differential expression of the cyclin D1a and D1b
isoforms may impact cancer development and progression at distinct levels.
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Figures
Figure 1. Cyclin D1a and cyclin D1b regulate overlapping and distinct gene
expression profiles. (A). Transcriptional activity of PPARγ, NRF1, and AR assayed in
HEK 293T cells. Cells were transfected with expression vectors for Gal4-AR, Gal4PPARγ or Gal4-NRF1 along with either 3xFLAG vector, 3x FLAG cyclin D1a, or 3x
FLAG cyclin D1b constructs and the reporter, pG5-LUC. The data represents triplicate
experiments and relative luciferase units based on the mean data normalized to basal
activity plus standard error of the mean (SEM). (B). Comparison of cyclin D1-regulated
genes determined by microarray analysis (For full details the GEO accession number
obtained is GSE9161
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zfellwagiuaagfa&acc=GSE9161).
-/-

Comparison is shown between cyclin D1 3T3 cells transduced with expression vectors
encoding cyclin D1a, cyclin D1b or control vector.

Figure 2. Cyclin D1a but not cyclin D1b enhances cellular migration. (A). Confocal
-/-

microscopy of cyclin D1 MEFs transduced with cyclin D1a or cyclin D1b retrovirus. (left
panel) F-actin staining and (right panel) paxillin (green), tyrosine phosphorylated paxillin
-/-

(Y118) (red) and DAPI (blue). Cyclin D1 MEFs were transduced with retroviral
expression plasmids encoding either the cyclin D1a or cyclin D1b isoform. The GFP
expressing cells were sorted by FACS and were then examined by confocal
microscopy. (B). Cellular velocity is shown as mean ± SEM. (C). Western blot analysis
-/-

of cyclin D1 MEFs transduced with retroviral expression vectors cyclin D1a or cyclin
D1b. Antibodies were directed
Downloaded from www.jbc.org at Thomas Jefferson University on February 5, 2008
KIP1

to FLAG (M2), p27 , phospho-cofilin (Ser3) (as a marker of activated Rho signaling),
and β-tubulin and vinculin as total protein loading controls.

Figure 3. Cyclin D1a but not cyclin D1b increases the abundance of p27

KIP1

-/-

protein. (A). Cyclin D1 MEFs were transduced with retroviral vectors for cyclin D1a or
cyclin D1b and subjected to Western blot analysis. A number was assigned for each
separate batch of MEFs generated and is indicated above each Western blot. (B).
Northern analysis for p27
(n=4).

KIP1

KIP1

(C). QT-PCR for p27

. Data are shown as mean ± SEM

Figure 4. Cyclin D1a increases p27
KIP1

KIP1

protein stability. (A,B) Measurement of

p27
protein degradation after inhibition of protein synthesis with cycloheximide
(CHX). Proliferating MEFs were transduced with the retroviral vectors as indicated and
were treated with 10 µg/ml cycloheximide for the indicated times. p27

KIP1

KIP1

levels were

measured by Western blot shown as representative example. P27
levels were
normalized to β-tubulin as a protein loading control and densitometric analysis of
KIP1

representative Western blot studies (B). (C) Pulse chase analysis for p27
abundance. A representative example is shown. The data are mean from densitometry
of n=3 separate experiments.

KIP1

Figure 5. Cyclin D1b is defective in p27 -binding. (A). Schematic representation of
cyclin D1 constructs used in (B, D) mammalian two hybrid. The cyclin D1 cDNAs shown
in (A) were linked to either the VP16 (left panel) transactivation domain or Gal4 (right
KIP1

panel) DNA binding domin. p27
was linked to the cognate mammalian 2-hybrid
interaction domain. The interaction is shown as relative luciferase activity for N>5
-/-

separate transfections as mean ± SEM. (C). Cyclin D1 MEFs transduced with retroviral

vectors for cyclin D1a or cyclin D1b were analyzed by Western blot (left hand panel) or
immunoprecipitation – Western blot. Cyclin D1 immunoprecipitation was conducted with
KIP1

the FLAG antibody with subsequent Western blot for cyclin D1 (DCS-6) or p27
(C19). (D). Interaction of cyclin D1 constructs with Cdk4 in mammalian 2-hybrid. The data
is shown throughout as mean ± SEM for N> 5 separate experiments.

